According to GuruFocus Insider Data, these are the largest CEO buys during the past week. The overall trend of CEOs is illustrated in the chart below:
Synta Pharmaceuticals Corp. (SNTA, Financial): President and CEO Safi R Bahcall Bought 10,000 Shares
President and CEO of Synta Pharmaceuticals Corp. (SNTA) Safi R Bahcall bought 10,000 shares on 06/29/2012 at an average price of $6.53. SYNTA PHARMACEUTICALS CORP. is a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases. Synta Pharmaceuticals Corp. has a market cap of $315.3 million; its shares were traded at around $6.53 with and P/S ratio of 41.6.
Synta recently reported its first quarter 2012 financial results. Total revenue was $0.1 million for the first quarter in 2012 compared to total revenue of $1.1 million for the same period in 2011. The Company reported a net loss of $15.1 million or $0.27per basic and diluted share for the first quarter in 2012, compared to a net loss of $11.4 million, or $0.27 per basic and diluted share for the same period in 2011.
Jean-Marie Eveillard bought 200,000 shares in the quarter that ended on 03/31/2012, which is 0.0035% of the $25.09 billion portfolio of First Eagle Investment Management, LLC.
VP, Fin. and Admin., CFO Keith S Ehrlich sold 4,397 shares of SNTA stock on 03/01/2012 at the average price of 4.7. Keith S Ehrlich owns at least 17,573 shares after this. The price of the stock has increased by 38.94% since. There are mixed trades from other insiders.
Methode Electronics Inc. (MEI, Financial): CEO Donald W Duda Bought 3,860 Shares
CEO of Methode Electronics Inc. (MEI) Donald W Duda bought 3,860 shares on 07/02/2012 at an average price of $8.5. Methode Electronics, Inc. manufactures component devices world-wide for Original Equipment Manufacturers of information processing and networking equipment, voice and data communications systems, consumer electronics, automobiles, aerospace vehicles and industrial equipment. Methode Electronics Inc. has a market cap of $315.3 million; its shares were traded at around $8.5 with a P/E ratio of 35.5 and P/S ratio of 0.7. The dividend yield of Methode Electronics Inc. stocks is 3.3%.
Methode Electronics recently reported its fiscal fourth quarter 2012 financial results. Net income decreased $4.3 million to $5.8 million, or $0.15 per share, in the fourth quarter of Fiscal 2012 from net income of $10.1 million, or $0.27 per share, in the same period of Fiscal 2011.
NWQ Managers bought 841,445 shares in the quarter that ended on 03/31/2012, which is 0.052% of the $14.95 billion portfolio of NWQ Investment Management Co. James Barrow owns 774,500 shares as of 03/31/2012, which accounts for 0.014% of the $50.84 billion portfolio of Barrow, Hanley, Mewhinney & Strauss. Mario Gabelli owns 210,500 shares as of 03/31/2012, which accounts for 0.014% of the $13.95 billion portfolio of GAMCO Investors.
CFO Douglas A Koman bought 3,616 shares of MEI stock on 07/02/2012 at the average price of 7.95. Douglas A Koman owns at least 199,042 shares after this. The price of the stock has increased by 6.92% since. Other insiders have also increased their positions in the company.
Paramount Gold and Silver Corp. (PZG, Financial): CEO Christopher Crupi Bought 10,000 Shares
CEO of Paramount Gold and Silver Corp. (PZG) Christopher Crupi bought 10,000 shares on 06/28/2012 at an average price of $2.4. Paramount Gold and Silver Corp. engages in the acquisition, exploration, and development of gold, silver, and precious metal properties primarily in Mexico. Paramount Gold And Silver Corp. has a market cap of $353.8 million; its shares were traded at around $2.4 with and P/S ratio of 1179.6.
CFO Carlo Buffone bought 20,000 shares of PZG stock on 03/29/2012 at the average price of 2.2. Carlo Buffone owns at least 20,000 shares after this. The price of the stock has increased by 9.09% since. Other insiders have also increased their positions in the company.
Marchex, Inc. (MCHX, Financial): CEO, 10% Owner Russell C Horowitz Bought 5,000 Shares
CEO, 10% Owner of Marchex, Inc. (MCHX) Russell C Horowitz bought 5,000 shares on 07/03/2012 at an average price of $3.93. Marchex Inc provides technology-based services to merchants engaged in online transactions. Marchex, Inc. has a market cap of $134.3 million; its shares were traded at around $3.93 with a P/E ratio of 361.1 and P/S ratio of 0.9. The dividend yield of Marchex, Inc. stocks is 2.2%.
CFO Michael A Arends bought 1,500 shares of MCHX stock on 05/18/2012 at the average price of 3.26. Michael A Arends owns at least 482,500 shares after this. The price of the stock has increased by 20.55% since. There are mixed trades from other insiders.
Cytomedix, Inc. (CMXI, Financial): CEO Martin P Rosendale Bought 8,000 Shares
CEO of Cytomedix, Inc. (CMXI) Martin P Rosendale bought 8,000 shares on 07/03/2012 at an average price of $1.35. Cytomedix, Inc. is a biotechnology company specializing in the research, development, licensing, and distribution of systems for autologous cellular therapies. Cytomedix, Inc. has a market cap of $106.7 million; its shares were traded at around $1.35 with and P/S ratio of 14.7.
Cytomedix recently reported its first quarter 2012 financial results. Total revenues increased 121% to $3.02 million from $1.37 million. Product sales increased 23% to $1.69 million from $1.37 million.
CFO Andrew Scott Maslan bought 5,000 shares of CMXI stock on 07/03/2012 at the average price of 1.08. Andrew Scott Maslan owns at least 102,780 shares after this. The price of the stock has increased by 25% since.
For the complete list of stocks that bought by their company CEOs, go to: CEO Buys.
Synta Pharmaceuticals Corp. (SNTA, Financial): President and CEO Safi R Bahcall Bought 10,000 Shares
President and CEO of Synta Pharmaceuticals Corp. (SNTA) Safi R Bahcall bought 10,000 shares on 06/29/2012 at an average price of $6.53. SYNTA PHARMACEUTICALS CORP. is a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases. Synta Pharmaceuticals Corp. has a market cap of $315.3 million; its shares were traded at around $6.53 with and P/S ratio of 41.6.
Synta recently reported its first quarter 2012 financial results. Total revenue was $0.1 million for the first quarter in 2012 compared to total revenue of $1.1 million for the same period in 2011. The Company reported a net loss of $15.1 million or $0.27per basic and diluted share for the first quarter in 2012, compared to a net loss of $11.4 million, or $0.27 per basic and diluted share for the same period in 2011.
Jean-Marie Eveillard bought 200,000 shares in the quarter that ended on 03/31/2012, which is 0.0035% of the $25.09 billion portfolio of First Eagle Investment Management, LLC.
VP, Fin. and Admin., CFO Keith S Ehrlich sold 4,397 shares of SNTA stock on 03/01/2012 at the average price of 4.7. Keith S Ehrlich owns at least 17,573 shares after this. The price of the stock has increased by 38.94% since. There are mixed trades from other insiders.
Methode Electronics Inc. (MEI, Financial): CEO Donald W Duda Bought 3,860 Shares
CEO of Methode Electronics Inc. (MEI) Donald W Duda bought 3,860 shares on 07/02/2012 at an average price of $8.5. Methode Electronics, Inc. manufactures component devices world-wide for Original Equipment Manufacturers of information processing and networking equipment, voice and data communications systems, consumer electronics, automobiles, aerospace vehicles and industrial equipment. Methode Electronics Inc. has a market cap of $315.3 million; its shares were traded at around $8.5 with a P/E ratio of 35.5 and P/S ratio of 0.7. The dividend yield of Methode Electronics Inc. stocks is 3.3%.
Methode Electronics recently reported its fiscal fourth quarter 2012 financial results. Net income decreased $4.3 million to $5.8 million, or $0.15 per share, in the fourth quarter of Fiscal 2012 from net income of $10.1 million, or $0.27 per share, in the same period of Fiscal 2011.
NWQ Managers bought 841,445 shares in the quarter that ended on 03/31/2012, which is 0.052% of the $14.95 billion portfolio of NWQ Investment Management Co. James Barrow owns 774,500 shares as of 03/31/2012, which accounts for 0.014% of the $50.84 billion portfolio of Barrow, Hanley, Mewhinney & Strauss. Mario Gabelli owns 210,500 shares as of 03/31/2012, which accounts for 0.014% of the $13.95 billion portfolio of GAMCO Investors.
CFO Douglas A Koman bought 3,616 shares of MEI stock on 07/02/2012 at the average price of 7.95. Douglas A Koman owns at least 199,042 shares after this. The price of the stock has increased by 6.92% since. Other insiders have also increased their positions in the company.
Paramount Gold and Silver Corp. (PZG, Financial): CEO Christopher Crupi Bought 10,000 Shares
CEO of Paramount Gold and Silver Corp. (PZG) Christopher Crupi bought 10,000 shares on 06/28/2012 at an average price of $2.4. Paramount Gold and Silver Corp. engages in the acquisition, exploration, and development of gold, silver, and precious metal properties primarily in Mexico. Paramount Gold And Silver Corp. has a market cap of $353.8 million; its shares were traded at around $2.4 with and P/S ratio of 1179.6.
CFO Carlo Buffone bought 20,000 shares of PZG stock on 03/29/2012 at the average price of 2.2. Carlo Buffone owns at least 20,000 shares after this. The price of the stock has increased by 9.09% since. Other insiders have also increased their positions in the company.
Marchex, Inc. (MCHX, Financial): CEO, 10% Owner Russell C Horowitz Bought 5,000 Shares
CEO, 10% Owner of Marchex, Inc. (MCHX) Russell C Horowitz bought 5,000 shares on 07/03/2012 at an average price of $3.93. Marchex Inc provides technology-based services to merchants engaged in online transactions. Marchex, Inc. has a market cap of $134.3 million; its shares were traded at around $3.93 with a P/E ratio of 361.1 and P/S ratio of 0.9. The dividend yield of Marchex, Inc. stocks is 2.2%.
CFO Michael A Arends bought 1,500 shares of MCHX stock on 05/18/2012 at the average price of 3.26. Michael A Arends owns at least 482,500 shares after this. The price of the stock has increased by 20.55% since. There are mixed trades from other insiders.
Cytomedix, Inc. (CMXI, Financial): CEO Martin P Rosendale Bought 8,000 Shares
CEO of Cytomedix, Inc. (CMXI) Martin P Rosendale bought 8,000 shares on 07/03/2012 at an average price of $1.35. Cytomedix, Inc. is a biotechnology company specializing in the research, development, licensing, and distribution of systems for autologous cellular therapies. Cytomedix, Inc. has a market cap of $106.7 million; its shares were traded at around $1.35 with and P/S ratio of 14.7.
Cytomedix recently reported its first quarter 2012 financial results. Total revenues increased 121% to $3.02 million from $1.37 million. Product sales increased 23% to $1.69 million from $1.37 million.
CFO Andrew Scott Maslan bought 5,000 shares of CMXI stock on 07/03/2012 at the average price of 1.08. Andrew Scott Maslan owns at least 102,780 shares after this. The price of the stock has increased by 25% since.
For the complete list of stocks that bought by their company CEOs, go to: CEO Buys.
